 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Efficacy of adjuvant imatinib therapy in GIST patients with KIT exon 9 mutations: a European multicenter retrospective study

Clin Cancer Res: Efficacy of adjuvant imatinib therapy in GIST patients with KIT exon 9 mutations: a European multicenter retrospective study

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

4 meals day

3 4 inches

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Gastric between intestinal stromal tumors (of GIST) occurs in digesting the most common type of sarcoma channel, characterized in that with KIT or PDGFRA mutations
.

The most common KIT mutation appears in exon 11, which is present in about 70% of cases

Gastric between intestinal stromal tumors between intestinal stromal tumors (of GIST) occurs in digesting the most common type of sarcoma channel, characterized in that with KIT or PDGFRA mutations

The study retrospectively collected data from 185 patients from 23 European GIST reference centers
.

Propensity score matching (PSM) and inverse probabilistic treatment weighting (IPTW) were used to explain confounding factors

The study retrospectively collected data from 185 patients from 23 European GIST reference centers

Of the 185 patients, 131 (70.

The median follow-up time for the entire population was 91.

Prognosis of the overall population

In the ID population, the median RFS of the 400 mg/d and 800 mg/d groups were 80.
6 months (95% CI 62.
1-126.
2) and 62.
0 months (95% CI 49.
8-99.
0), respectively
.

The Kaplan-Meier curve of the PSM population indicated a univariate HR of 1.

In the ID population, the median RFS of the 400 mg/d and 800 mg/d groups were 80.

The mRFS analysis population included 90 patients in the 400 mg/d group and 42 patients in the 800 mg/d group
.

The median mRFS of the 400 mg/d group and 800 mg/d group were 106.

The mRFS analysis population included 90 patients in the 400 mg/d group and 42 patients in the 800 mg/d group

In the IFFS analysis, the ID population is used
.

The median IFFS in the 400 mg/d and 800 mg/d groups were 135.

In the IFFS analysis, the ID population is used
.
The median IFFS in the 400 mg/d and 800 mg/d groups were 135.
8 months (95% CI 111.
0-unlimited) and 91.
0 months (95% CI 67.
3-unlimited), respectively
.
The HR of the PSM population was 1.
78 (95% CI 0.
93-3.
42)
.
In the IPTW analysis, the HR was 1.
30 (95% CI 0.
77-2.
20)
.
In the IFFS analysis, the ID population is used
.
The median IFFS in the 400 mg/d and 800 mg/d groups were 135.
8 months (95% CI 111.
0-unlimited) and 91.
0 months (95% CI 67.
3-unlimited), respectively
.
The HR of the PSM population was 1.
78 (95% CI 0.
93-3.
42)
.
In the IPTW analysis, the HR was 1.
30 (95% CI 0.
77-2.
20)
.

In the OS analysis, the ID population is used
.
The median OS in the 400 mg/d and 800 mg/d groups was 220.
8 months (95% CI 174.
2-unlimited) and 248.
5 months (95% CI 106.
0-unlimited), respectively
.
In the IPTW analysis, the HR was 0.
81 (95% CI 0.
32-2.
07)
.
In OS analysis, ID population is used
.
The median OS in the 400 mg/d and 800 mg/d groups was 220.
8 months (95% CI 174.
2-unlimited) and 248.
5 months (95% CI 106.
0-unlimited), respectively
.
In the IPTW analysis, the HR was 0.
81 (95% CI 0.
32-2.
07)
.

In summary, this retrospective study showed that GIST patients with KIT exon 9 mutations received adjuvant imatinib treatment, and the daily dose of 800 mg did not have a better outcome in terms of survival and prognosis than 400 mg daily
.
This retrospective study showed that GIST patients with KIT exon 9 mutations received adjuvant imatinib treatment, and a daily dose of 800 mg did not have a better survival prognosis than 400 mg a day
.
This retrospective study showed that GIST patients with KIT exon 9 mutations received adjuvant imatinib treatment, and a daily dose of 800 mg did not have a better survival prognosis than 400 mg a day
.

Original source:

Vincenzi B, Napolitano A, Fiocco M, et al.
Adjuvant imatinib in GIST patients harboring exon 9 KIT mutations: results from a multi-institutional European retrospective study.
Clin Cancer Res.
2021 Oct 6: clincanres.
1665.
2021.
doi: 10.
1158/1078 -0432.
CCR-21-1665.
Epub ahead of print.
PMID: 34615721.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.